GenFleet Therapeutics-B (02595.HK): GFH375 (oral KRAS G12D inhibitor) Phase II monotherapy superior data in previously treated NSCLC to be presented as an oral presentation at the 2026 World Conference on Lung Cancer

date
23/09/2026
Zhitong Finance APP news, GenFleet Therapeutics-B (02595.HK) announced that updated Phase II trial data for GFH375 monotherapy in previously treated KRAS G12D-mutant non-small cell lung cancer was presented as an oral report on September 14 local time at this year's World Conference on Lung Cancer (WCLC) held in Seoul.
Latest
See all latestmore